A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS

被引：476

作者：

BALFOUR, HH

CHACE, BA

STAPLETON, JT

SIMMONS, RL

FRYD, DS

机构：

[1] UNIV PITTSBURGH, DEPT SURG, PITTSBURGH, PA 15260 USA

[2] UNIV MINNESOTA, HLTH SCI CTR, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA

[3] UNIV MINNESOTA, HLTH SCI CTR, DEPT PATHOL, MINNEAPOLIS, MN 55455 USA

[4] UNIV MINNESOTA, HLTH SCI CTR, DEPT SURG, MINNEAPOLIS, MN 55455 USA

[5] UNIV MINNESOTA, HLTH SCI CTR, DEPT BIOMETRY, MINNEAPOLIS, MN 55455 USA

[6] UNIV IOWA, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1989年 / 320卷 / 21期

关键词：

D O I：

10.1056/NEJM198905253202105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1381 / 1387

页数：7

共 31 条

[1] ACYCLOVIR IN IMMUNOCOMPROMISED PATIENTS WITH CYTOMEGALOVIRUS DISEASE - A CONTROLLED TRIAL AT ONE INSTITUTION [J].

BALFOUR, HH ;

BEAN, B ;

MITCHELL, CD ;

SACHS, GW ;

BOEN, JR ;

EDELMAN, CK .

AMERICAN JOURNAL OF MEDICINE, 1982, 73 (1A) :241-248

[2]

BALFOUR HH, 1985, ADV THERAPY HERPESVI, P35

[3] METABOLIC-ACTIVATION OF THE NUCLEOSIDE ANALOG 9-([2-HYDROXY-L-(HYDROXYMETHYL)ETHOXY]METHYL)GUANINE IN HUMAN-DIPLOID FIBROBLASTS INFECTED WITH HUMAN CYTOMEGALO-VIRUS [J].

BIRON, KK ;

STANAT, SC ;

SORRELL, JB ;

FYFE, JA ;

KELLER, PM ;

LAMBE, CU ;

NELSON, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (08) :2473-2477

[4]

BUHLES WC, 1988, REV INFECT DIS, V10, pS495

[5] ACQUISITION OF DONOR STRAINS OF CYTOMEGALOVIRUS BY RENAL-TRANSPLANT RECIPIENTS [J].

CHOU, SW .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (22) :1418-1423

[6] INVITRO SUSCEPTIBILITY OF CYTOMEGALOVIRUS ISOLATES FROM IMMUNOCOMPROMISED PATIENTS TO ACYCLOVIR AND GANCICLOVIR [J].

COLE, NL ;

BALFOUR, HH .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1987, 6 (03) :255-261

[7]

DEWOLF F, 1988, LANCET, V1, P373

[8] CYTOMEGALO-VIRUS PNEUMONIA AFTER BONE-MARROW TRANSPLANTATION SUCCESSFULLY TREATED WITH THE COMBINATION OF GANCICLOVIR AND HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN [J].

EMANUEL, D ;

CUNNINGHAM, I ;

JULESELYSEE, K ;

BROCHSTEIN, JA ;

KERNAN, NA ;

LAVER, J ;

STOVER, D ;

WHITE, DA ;

FELS, A ;

POLSKY, B ;

CASTROMALASPINA, H ;

PEPPARD, JR ;

BARTUS, P ;

HAMMERLING, U ;

OREILLY, RJ .

ANNALS OF INTERNAL MEDICINE, 1988, 109 (10) :777-782

[9] GANCICLOVIR TREATMENT OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED HOSTS [J].

ERICE, A ;

JORDAN, C ;

CHACE, BA ;

FLETCHER, C ;

CHINNOCK, BJ ;

BALFOUR, HH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (22) :3082-3087

[10] HUMAN PHARMACOKINETICS OF THE ANTIVIRAL DRUG DHPG [J].

FLETCHER, C ;

SAWCHUK, R ;

CHINNOCK, B ;

DEMIRANDA, P ;

BALFOUR, HH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) :281-286

← 1 2 3 4 →